A Chinese medicine composition for treating gynecological diseases

By using traditional Chinese medicine compositions containing medicinal materials such as Rehmannia and wolfberry, effective ovarian function recovery and hormone balance are achieved in response to amenorrhea problems, especially liver and kidney deficiency or yin deficiency and blood-drying type, and the existing treatment methods are solved The problems of poor efficacy and major side effects provide a safe and efficient treatment plan.

CN118203628BActive Publication Date: 2024-11-22LUNAN PHARMA GROUP CORPORATION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410314028.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-19
Publication Date
2024-11-22
Estimated Expiration
2044-03-19

AI Technical Summary

Technical Problem

Among the existing methods for treating amenorrhea, Western medicine hormone treatment has problems of large side effects and poor efficacy. Traditional Chinese medicine has slow effect and lacks Chinese medicine compositions with strong targeted and accurate efficacy.

Method used

Using traditional Chinese medicine compositions including Rehmannia, wolfberry, Cuscuta, Angelica sinensis, Codonopsis, Ligustrum, Xiangfu, Motherwort and other raw materials, combined with traditional Chinese medicine theory, targeting the liver and kidneys through the effects of nourishing the liver and kidneys, nourishing blood, promoting blood circulation, and regulating menstruation. Kidney deficiency type or yin deficiency type blood dry type amenorrhea has significant effects.

Benefits of technology

This traditional Chinese medicine composition can effectively improve ovarian function, restore follicle development, balance hormone levels, significantly improve secondary amenorrhea, have accurate efficacy, small side effects, high safety, and are better than estrogen therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004748405720000021
    Figure BDA0004748405720000021
  • Figure BDA0004748405720000031
    Figure BDA0004748405720000031
  • Figure BDA0004748405720000032
    Figure BDA0004748405720000032
Patent Text Reader

Abstract

The present invention belongs to the technical field of traditional Chinese medicine, and specifically provides a traditional Chinese medicine composition for treating gynecological diseases, comprising raw medicinal materials such as Radix Rehmanniae Preparata, Fructus Lycii, Semen Cuscutae, Radix Angelicae Sinensis, Codonopsis Pilosula, Fructus Ligustri Lucidi, Rhizoma Cyperi, and Herba Leonuri. The composition of the present invention can restore the ovarian index of mice with amenorrhea caused by immune premature ovarian failure to normal; can effectively improve the disorder of estrous cycle of the body and restore the normal development of follicles; can improve the endocrine dysfunction of the ovaries of the model mice and balance and regulate the levels of various hormones. The traditional Chinese medicine composition of the present invention has definite efficacy, small side effects, high safety, and better effect than estrogen. It has significant efficacy for female secondary amenorrhea, especially for amenorrhea of ​​liver and kidney deficiency type or yin deficiency and blood dryness type.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating gynecological diseases. Background Art

[0002] Amenorrhea is a common gynecological disease and a common symptom in women. The causes are complicated and include genetic, developmental, endocrine, immune, and mental factors. It can also be caused by tumors, trauma, and drugs. In today's society, competition is fierce, and women are under great pressure in the workplace. Coupled with a fast-paced lifestyle, irregular diet, and unbalanced nutrition intake, regular meals are often replaced by fast food and boxed meals, which leads to insufficient essence, qi, and blood in the body and excessive consumption, which in turn causes the body's blood sea to be insufficient and Chong and Ren to be deficient, thus causing the high frequency of amenorrhea.

[0003] In addition to a normal endometrium, normal menstruation requires the presence of normally developed follicles and ovulation in the ovaries. The gonadotropin-releasing hormone (FSH-RF and LH-RF) secreted by the hypothalamus stimulates the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH acts on the ovaries to promote the continuous development of follicles, which secrete estrogen during development. After ovulation, the follicle forms a corpus luteum, which secretes estrogen and progesterone. This sex hormone acts cyclically on the normal endometrium, resulting in menstruation.

[0004] Modern medicine believes that the causes of amenorrhea are very complex. Dysfunctions in all links of the hypothalamus-pituitary-ovary-uterus axis can cause amenorrhea, and there are no less than 30 types. It can be roughly divided into physiological amenorrhea, primary amenorrhea and secondary amenorrhea. Those who have no menstruation due to pregnancy, breastfeeding or menopause are called physiological amenorrhea; those who are over 16 years old, have developed secondary sexual characteristics, and have not yet had menstruation, or those who are over 14 years old, have not yet developed secondary sexual characteristics, and have no menstruation, are called primary amenorrhea; those who have established normal menstruation in the past, but have stopped menstruating for 6 months due to some pathological reasons, or those who have stopped menstruating for more than 3 cycles according to their original menstrual cycles, are called secondary amenorrhea.

[0005] Traditional Chinese medicine believes that the core pathogenesis of amenorrhea is the imbalance of Chong and Ren Qi and blood, which can be divided into two aspects. Deficiency refers to weak Qi and blood, or kidney deficiency or spleen deficiency, Chong and Ren deficiency, and no blood can flow; excess refers to phlegm stagnation or cold stagnation and blood stasis, or liver depression, qi stagnation and blood stasis, which block the cell vessels and prevent menstrual blood from flowing. Common clinical syndromes are as follows: Liver-kidney deficiency, insufficient menstrual blood type: The liver is responsible for storing blood, and the kidney is responsible for storing essence. Deficiency of essence and blood makes the blood sea unable to be full and leads to insufficient essence and blood; spleen-stomach deficiency, qi and blood deficiency type: Deficiency of spleen and stomach cannot transform qi, blood and essence and distribute them throughout the body, resulting in the loss of nourishment of Chong, Ren and uterus, and the emptiness of blood sea; liver-qi stagnation, poor blood circulation type: The liver's qi is blocked and cannot promote blood circulation, resulting in poor menstruation; yin deficiency and blood dryness type: Yin fluid is damaged, virtual heat is accumulated, blood is damaged, and blood deficiency leads to amenorrhea; cold stagnation and blood stasis type: cold evil stagnates, blood coagulates when it encounters cold, resulting in stagnation of Chong and Ren, obstruction of uterine vessels, and amenorrhea; phlegm-dampness obstruction type: phlegm-dampness obstructs the body, hindering qi and blood, poor blood circulation, Chong and Ren obstructions, obstruction of uterus, and absent menstruation.

[0006] To treat amenorrhea, we must first exclude physiological amenorrhea and organic lesions. Physiological amenorrhea mainly includes amenorrhea caused by pregnancy, perimenopausal syndrome, etc.; amenorrhea caused by organic lesions mainly includes hymen occlusion, vaginal occlusion, pituitary gland, ovary and other parts of the tumor. Western medicine often uses progesterone, estrogen and induced ovulation. This method can better improve the patient's physical condition, thereby relieving the symptoms of amenorrhea and achieving a certain therapeutic effect. However, it should be noted that many current studies have shown that the use of conventional Western medicine does not have a good effect on patients with amenorrhea, and may even cause more complications, and it is very easy to relapse after stopping the drug. Traditional Chinese medicine has a unique holistic concept and treatment principles and ideas of syndrome differentiation and treatment. Therefore, people often treat amenorrhea from the perspective of traditional Chinese medicine in order to achieve better results.

[0007] In traditional Chinese medicine, the treatment of amenorrhea is nothing more than "tonifying the deficiency and purging the excess". Amenorrhea of ​​liver and kidney deficiency type should be treated by nourishing blood and menstruation to nourish the liver and kidney; amenorrhea of ​​spleen and stomach deficiency type should be treated by regulating qi and blood to strengthen the spleen and nourish the stomach; amenorrhea of ​​qi stagnation and blood stasis type should be treated by activating blood circulation and promoting qi circulation; amenorrhea of ​​yin deficiency and blood dryness type should be treated by nourishing yin to clear the deficiency fire; amenorrhea of ​​cold stagnation and blood stasis type should be treated by dispelling cold and unblocking menstruation, warming the menstruation and activating blood circulation; amenorrhea of ​​phlegm and dampness stagnation type should be treated by resolving phlegm and removing dampness.

[0008] At present, there is no special method or effective medicine for the treatment of amenorrhea. Western medicine uses hormones to treat amenorrhea, which has serious side effects and poor efficacy. In recent years, Chinese medicine has made great achievements in the treatment of amenorrhea, but most Chinese medicines are slow to take effect and lack a targeted and effective Chinese medicine combination. Summary of the invention

[0009] The object of the present invention is to provide a Chinese medicine composition for treating amenorrhea, comprising raw medicinal materials such as Radix Rehmanniae Preparata, Fructus Lycii, Semen Cuscutae, Radix Angelicae Sinensis, Fructus Ligustri Lucidi, Rhizoma Cyperi, Herba Leonuri, etc. The composition of the present invention has a definite curative effect, especially for amenorrhea of ​​liver and kidney deficiency type or yin deficiency and blood dryness type.

[0010] The technical solution of the present invention is as follows:

[0011] A traditional Chinese medicine composition for treating amenorrhea comprises prepared rehmannia root, wolfberry fruit, dodder seed, angelica root, codonopsis pilosula, glossy privet fruit, cyperus rotundus and motherwort.

[0012] Preferably, the traditional Chinese medicine composition also includes raw medicinal materials such as deer antler powder, tortoise shell, eucommia bark, fructus aurantii, and liquorice.

[0013] Preferably, the Chinese medicine composition further comprises raw medicinal materials such as epimedium, raspberry, schisandra chinensis, chuanxiong, and liquidambar formosana.

[0014] Preferably, the Chinese medicine composition comprises the following components in parts by weight:

[0015]

[0016]

[0017] Further preferably, the Chinese medicine composition comprises the following components in parts by weight:

[0018]

[0019] In a preferred embodiment, the Chinese medicine composition comprises the following components in parts by weight:

[0020]

[0021] In another embodiment, the Chinese medicine composition comprises the following components in parts by weight:

[0022]

[0023] According to Chinese medicine, the kidney stores essence and is responsible for reproduction, while the liver stores blood and is responsible for dredging. Traditional medicine generally believes that the liver and kidney have the same origin, and the production of blood depends on the gasification of the essence in the kidney; the fullness of the essence in the kidney depends on the nourishment of blood. In Chinese medicine, the kidney and liver are related to the menstrual cycle. The opening and closing of kidney qi determines the fullness and overflow of the Chong and Ren blood sea, thus forming the menstrual cycle. Therefore, in the clinical treatment of gynecological diseases, the kidney is often given priority, and the liver and kidney are treated together.

[0024] In the formula, Radix Rehmanniae and Fructus Lycii are the main drugs. Radix Rehmanniae replenishes essence, nourishes kidney and produces marrow, nourishes liver, replenishes blood and nourishes yin; Fructus Lycii nourishes liver and kidney, replenishes essence and nourishes yin; the two are used together to nourish liver and kidney, replenish blood and nourish yin. Cuscuta chinensis nourishes liver and kidney, Angelica sinensis replenishes blood and promotes blood circulation, Codonopsis pilosula nourishes blood and produces body fluid, Fructus Ligustri Lucidi nourishes liver and kidney, Deer Horn Frost nourishes yin and stops bleeding, Tortoise Shell nourishes yin and nourishes blood, Eucommia ulmoides nourishes liver and kidney, and the above are all ministerial drugs, which help the main drugs to play the role of nourishing liver and kidney, replenishing blood and nourishing yin. Cyperus rotundus soothes liver and regulates qi, Citrus aurantium promotes qi and relieves bloating, Epimedium nourishes kidney and warms yang, Rubus idaeus nourishes kidney and consolidates essence, Schisandra chinensis nourishes kidney and produces body fluid, Leonurus japonicus promotes blood circulation and regulates menstruation, Ligusticum chuanxiong promotes qi and blood circulation, and Rhizoma Smilacis Glabrae dispels wind and activates collaterals, and the above are all adjuvant drugs, which assist the main and ministerial drugs to strengthen the effects of nourishing liver and kidney, nourishing yin and replenishing blood. Licorice is the guiding drug, harmonizing other drugs to achieve the effects of nourishing the liver and kidneys, promoting qi and nourishing yin, and replenishing blood and activating blood circulation.

[0025] The second aspect of the present invention provides a medicine, which includes the traditional Chinese medicine composition described in the present invention.

[0026] Preferably, the medicine is in the form of granules, mixtures, oral liquids, pills, capsules or tablets.

[0027] The third aspect of the present invention provides a method for preparing the Chinese medicine composition, wherein the Chinese medicine raw materials of the above formula are extracted or processed in other ways to prepare a pharmaceutically active substance, and the substance is used as a raw material, and a pharmaceutically acceptable auxiliary material is added when necessary, and various pharmaceutically acceptable dosage forms are prepared according to conventional techniques of pharmacy. The active substance is obtained by extracting the Chinese medicine raw materials separately, extracting the Chinese medicine raw materials together, or other methods, such as: crushing, soaking, extraction, percolation, distillation, decoction, concentration, alcohol precipitation, water precipitation, centrifugation, filtration, chromatography, drying, sieving, etc. These active substances can be substances in the form of extracts, which can be dry extracts or fluid extracts, and different concentrations can be prepared according to different preparation requirements.

[0028] The preferred processing method is as follows: the medicinal material is decocted with water for 1-3 times, each time for 1-3 hours, and 6-12 times the amount of water is added each time. The decoction is filtered, combined, and concentrated under reduced pressure to an extract with a relative density of 1.0-1.4 (50-60° C.), and placed at room temperature. If necessary, ethanol is added to make the alcohol content reach 60%-80%, and the extract is fully stirred, allowed to stand, filtered, and the filtrate is concentrated under reduced pressure to recover the ethanol. The concentrate is added with pharmaceutically acceptable excipients to prepare an oral liquid preparation or dried into a dry powder and then added with pharmaceutically acceptable excipients to prepare an oral solid preparation.

[0029] The preparation method of the Chinese medicine composition comprises the following steps:

[0030] (1) The above 18 raw medicinal materials are cleaned, washed and dried. Among them, Rehmannia root, Cyperus rotundus and Chuanxiong are cut into thick slices; Codonopsis pilosula and Licorice root are soaked thoroughly, cut into thick slices and dried; Citrus aurantium and Angelica sinensis are soaked thoroughly, cut into thin slices and dried; Leonurus japonicus is quickly washed, slightly moistened, cut and dried; Deer antler powder and Schisandra chinensis are crushed; Tortoise shell is steamed in boiling water for 45 minutes, put in hot water to remove the skin and flesh, washed and dried; Eucommia ulmoides is scraped off the rough skin, washed, cut into pieces and dried; Epimedium is picked and leaves are sprayed with clean water, slightly moistened, cut into strips and dried; and set aside for use;

[0031] (2) taking the raw medicinal material slices processed in step (1) in the prescribed amount, adding 6-12 times of water and boiling and extracting 2-3 times, each time for 1-3 hours; filtering, collecting and combining the decoction, and concentrating under reduced pressure to a relative density of 1.05-1.4 (50-60° C.), to obtain an extract;

[0032] (3) adding pharmaceutically acceptable excipients to the extract obtained in step (2) and preparing the extract into a clinically acceptable dosage form through conventional processes.

[0033] Preferably, the pharmaceutically acceptable excipient is one or more of a filler, a diluent, a flavoring agent, a lubricant, a preservative, a binder, a disintegrant, and a preservative.

[0034] Further preferably, the pharmaceutically acceptable excipients include but are not limited to lactose, starch, dextrin, powdered sugar, magnesium stearate, maltose, lemonade, tartaric acid, sodium hydroxide, aspartame, stevioside, cyclamate, protein sugar, acesulfame potassium, aspartame, sucralose and the like.

[0035] Preferably, the clinically acceptable dosage form is granules, tablets, pills, capsules, decoctions, oral liquids or mixtures.

[0036] In one embodiment, the Chinese medicine composition is a granule, which is prepared by the following method:

[0037] (1) The above 18 raw medicinal materials are cleaned, washed and dried. Among them, cooked rehmannia, cyperus rotundus and chuanxiong are cut into thick slices; codonopsis pilosula and liquorice are soaked thoroughly, cut into thick slices and dried; fructus aurantii and angelica are soaked thoroughly, cut into thin slices and dried; motherwort is quickly washed, slightly moistened, cut and dried; antler powder and schisandra chinensis are crushed; tortoise shell is steamed in boiling water for 45 minutes, put in hot water to remove the skin and flesh, washed and dried; the rough skin of eucommia is scraped off, washed, cut into pieces and dried; the leaves of epimedium are picked, sprayed with clean water, slightly moistened, cut into strips and dried; and set aside for use;

[0038] (2) taking the 18 raw medicinal materials processed in step (1) in the prescribed amount, adding 6-12 times of water and boiling and extracting 2-3 times, each time for 1-3 hours; filtering, collecting and combining the decoction, and concentrating under reduced pressure to an extract with a relative density of 1.1-1.4 at 50° C.-60° C.;

[0039] (3) The extract obtained in step (2) is vacuum dried to obtain a dry paste, and pharmaceutically acceptable excipients are added, dry granulated or wet granulated, granulated, and dried to obtain granules.

[0040] In another embodiment, the Chinese medicine composition is an oral liquid preparation, which is prepared by the following method:

[0041] (1) The above 18 raw medicinal materials are cleaned, washed and dried. Among them, cooked rehmannia, cyperus rotundus and chuanxiong are cut into thick slices; codonopsis pilosula and liquorice are soaked thoroughly, cut into thick slices and dried; fructus aurantii and angelica are soaked thoroughly, cut into thin slices and dried; motherwort is quickly washed, slightly moistened, cut and dried; antler powder and schisandra chinensis are crushed; tortoise shell is steamed in boiling water for 45 minutes, put in hot water to remove the skin and flesh, washed and dried; the rough skin of eucommia is scraped off, washed, cut into pieces and dried; the leaves of epimedium are picked, sprayed with clean water, slightly moistened, cut into strips and dried; and set aside for use;

[0042] (2) taking the ten medicinal materials processed in step (1) in the prescribed amount, adding 6-12 times of water and boiling and extracting for 2-3 times, each time for 1-3 hours; filtering, collecting and combining the decoctions, and concentrating under reduced pressure to an extract having a relative density of 1.05-1.15 at 50-60° C.;

[0043] (3) adding ethanol to the extract obtained in step (2) until the alcohol content is 60%-80%, cooling and settling for 24-48 hours, filtering and obtaining the alcohol precipitate for later use;

[0044] (4) recovering ethanol by vacuum concentration and concentrating to obtain an extract or a liquid for preparation; adding a flavoring agent and / or a preservative, adjusting the pH, adding water to the total amount of preparation, stirring, filtering, filling, and sterilizing to obtain an oral liquid preparation.

[0045] The fourth aspect of the present invention provides the use of the composition in preparing a drug for treating female amenorrhea, especially having a definite therapeutic effect on secondary amenorrhea caused by ovarian dysfunction.

[0046] The beneficial effects of the present invention are as follows: (1) The composition of the present invention can restore the decimal ovarian index of the amenorrhea model caused by immune premature ovarian failure to normal. (2) The composition of the present invention can effectively improve the body's estrous cycle disorder and restore the normal development of follicles. (3) The Chinese medicine composition of the present invention can improve the ovarian endocrine dysfunction of the model mouse and balance the levels of various hormones. (4) The Chinese medicine composition of the present invention has definite efficacy, few side effects, high safety, and better effect than estrogen. It has a significant effect on female secondary amenorrhea, especially for amenorrhea of ​​liver and kidney deficiency type or yin deficiency and blood dryness type.

[0047] In order to verify the efficacy of the Chinese medicine composition of the present invention, the inventors have carried out a large number of pharmacodynamic tests and studies. It should be noted that the drugs selected for the pharmacodynamic tests of the present invention are drugs obtained by the representative formulas and preparation methods of the present invention. Due to space limitations, the tests and results involved in the drugs obtained by other formulas and preparation methods included in the present invention are not listed here.

[0048] Experimental Example 1 Effect of the composition of the present invention on the amenorrhea rat model induced by Tripterygium wilfordii polyglycosides

[0049] 1 Experimental Materials

[0050] 1.1 Experimental animals

[0051] Healthy female SD rats (provided by the Pharmacology Center of Lunan Pharmaceutical Group) with a body weight of 200±20g were first adaptively fed for 3 days, and then vaginal smears were performed for 5 consecutive days. Rats with estrous cycles were included in the experimental group.

[0052] 1.2 Experimental Reagents

[0053] Tripterygium wilfordii polyglycosides tablets, national medicine standard Z42021212, Huangshi Feiyun Pharmaceutical Co., Ltd.; estradiol valerate tablets, national medicine standard J20171038, Bayer Healthcare Co., Ltd.; the composition of the present invention: the granules prepared in Example 1. Composition control group 1: the concentrated decoction prepared in comparison with Example 1; Composition control group 2: the concentrated decoction prepared in comparison with Example 2. Follicle stimulating hormone (FSH) ELISA kit, luteinizing hormone (LH) ELISA kit, estradiol (E2) ELISA kit, Shanghai ELISA Biotechnology.

[0054] 2 Test methods

[0055] 2.1 Animal grouping, modeling and drug administration

[0056] The rats included in the experiment were randomly divided into 6 groups, namely, a blank control group, a model control group, a positive control group, a composition control group 1, a composition control group 2, and a composition group of the present invention.

[0057] Except for the blank control group, rats in other groups were gavaged with 50 mg / kg of Tripterygium wilfordii glycosides tablets once a day for 14 consecutive days to establish the model.

[0058] After the modeling was completed, each group was gavaged with the corresponding drugs; the positive control was administered with 0.09 mg / kg of estradiol valerate tablets, the composition control group 1 was administered with 28.7 g of raw medicinal materials / kg of the concentrated decoction prepared in Comparative Example 1; the composition control group 2 was administered with 16.0 g of raw medicinal materials / kg of the concentrated decoction prepared in Comparative Example 2; the composition group of the present invention was administered with 18.4 g of raw medicinal materials / kg of the granules prepared in Example 1; the blank control and the model control group were administered with an equal volume of distilled water (10 mg / kg), once a day, for 6 consecutive weeks.

[0059] 2.2 Index detection

[0060] 2.2.1 Determination of serum sex hormone levels

[0061] 24 hours after the last administration, blood was collected from the abdominal aorta and centrifuged at 3000 rpm for 15 min to separate the serum. The levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) in the serum were determined using ELISA kits.

[0062] 2.2.2 Histological observation of rat ovaries

[0063] The rats were killed, dissected, and the ovaries were taken out and weighed. The ovaries were fixed in 10% formaldehyde, washed with gradient ethanol, embedded in paraffin, sliced, stained with HE, and the development of follicles was observed under an optical microscope.

[0064] 2.2.3 Data processing

[0065] SPSS 22.0 software was used for statistical analysis, and the data were expressed as mean ± standard deviation ( ) indicated that one-way analysis of variance was used for analysis among multiple groups, and P < 0.05 was considered statistically significant.

[0066] 3 Test results

[0067] 3.1 Effect of the composition of the present invention on serum sex hormones in model rats

[0068] After modeling, the serum sex hormones of rats in the model group were disordered. Compared with the blank control group, the levels of FSH and LH in the serum were significantly increased, and the level of E2 was significantly decreased, indicating that the modeling was successful after intragastric administration of Tripterygium wilfordii polyglycosides. After administration, each drug-administered group could regulate the serum sex hormone levels of rats, specifically, significantly reduce the levels of FSH and LH in the serum, and increase the level of E2; but the positive control and the composition group of the present invention were statistically significant relative to the model control group.

[0069] Table 1 Determination of serum sex hormone levels in rats of each group (n=10, )

[0070]

[0071]

[0072] Note: Compared with the blank control group, **P<0.01, ***P<0.001; compared with the model control group, # P<0.05, ## P<0.01.

[0073] 3.2 Histological observation of ovaries of rats in each group

[0074] Pathological histological examination showed that the ovarian primordial follicles, primary follicles, secondary follicles and other follicles at all levels in the blank control group were actively growing, with more mature granulosa cells, more follicular fluid content, large corpus luteum, rich cells, and normal ovarian structure. The model control group rats showed that the number of follicles in each stage was significantly reduced compared with the blank control group, the number of corpora lutea was reduced, and some hyperplastic fibers and hyperplastic fibroblasts were seen. There was congestion and congestion in the interstitial blood vessels of the hyperplastic fibers, and inflammatory cell infiltration was visible. Some follicles were cystic, the granulosa cells were of different sizes, the arrangement was disordered and irregular, and the cell size was uneven. The follicles at all levels of the rats in each drug administration group increased to varying degrees, the follicles grew actively, the mature follicles increased, the granulosa cells had more layers, the follicular fluid content increased, the corpus luteum increased, and the development was good. The positive control group and the composition group of the present invention were the most significant. The results are shown in Table 2.

[0075] Table 2 Ovarian follicle development in rats of each group (n=10, )

[0076]

[0077] Note: Compared with the blank control group, **P<0.01, ***P<0.001; compared with the model control group, # P<0.05, ## P<0.01, ### P<0.001.

[0078] Experimental Example 2 Effect of Chinese herbal medicine composition on mice with ovarian dysfunction and amenorrhea model

[0079] 1 Experimental Materials

[0080] 1.1 Experimental animals

[0081] 60 healthy female BALB / c mice (provided by the Pharmacology Center of Lunan Pharmaceutical Group), 6-8 weeks old, with a body weight of 20±2g, all of which had normal estrous cycles as screened by vaginal exfoliated cell smear. They were raised in a clean environment, with a room temperature of 18-22°C, a relative humidity of 40%-60%, a light intensity of 12h, and normal feed, with free access to food and water.

[0082] 1.2 Experimental instruments and reagents

[0083] Mouse zona pellucida polypeptide solution, amino acid sequence 330-342 of mouse zona pellucida 3 (ZP3) (NSSSSQFQIHGPR), analytical purity > 90%, Hangzhou Zhongpeptide Biochemical Co., Ltd.; Freund's complete adjuvant (CFA), Freund's incomplete adjuvant (IFA), Sigma, USA; estradiol (E2), luteinizing hormone (LH), follicle-stimulating hormone (FSH) radioimmunoassay kit, Beijing North Institute of Biotechnology, rabbit anti-mouse TGF-βR, TGF-βRII, Smad4 polyclonal antibodies, Wuhan Boster Bioengineering Co., Ltd.; VEGF polyclonal antibody, Proteinthch; secondary antibody PV9000, Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.; LEICADMLB2 binocular microscope, LEICARM2255 fully automatic rotary slicer, LEICA, Germany; estradiol valerate tablets, national medicine standard J20171038, Bayer Pharmaceuticals & Healthcare Co., Ltd.; composition of the present invention: granules prepared in Example 1.

[0084] 2 Experimental methods

[0085] 2.1 Animal modeling, grouping and drug administration

[0086] Except for the blank control group, the remaining 50 mice were modeled as follows: 6 mg ZP3 transparent polypeptide powder was taken, added to 6 ml double distilled water to prepare a solution, and then mixed with Freund's complete adjuvant at a ratio of 1:1 to prepare an immune preparation, and mixed with Freund's incomplete adjuvant at a ratio of 1:1 to prepare an immune enhancement reagent. At 9 am every day, each mouse was injected with 0.15 ml of the immune reagent into the soles of both hind feet and subcutaneous abdominal cavity. After 14 days, 0.15 ml of the immune enhancement reagent was injected into the soles of both feet and subcutaneous abdominal cavity again to strengthen immunity and establish an immune premature ovarian failure model. When modeling the blank control group, each mouse was injected with 0.15 ml of normal saline into the soles of both hind feet and subcutaneous abdominal cavity.

[0087] After modeling, 50 mice were randomly divided into model control group, positive control group, low-dose, medium-dose and high-dose groups of the combination, with 10 mice in each group and 10 mice in blank control group, for a total of 60 mice.

[0088] The positive control group was administered 0.13 mg / kg / day of estradiol valerate tablets; estradiol valerate tablets were dissolved to prepare a 0.01 mg / ml solution. The low, medium and high dose groups of the composition were administered with the granules of the embodiment, 13.3 g of raw medicinal materials / kg / day, 26.5 g of raw medicinal materials / kg / day, and 53.0 g of raw medicinal materials / kg / day, respectively; the blank control group and the model control group were both administered with an equal volume of normal saline. All the above groups were administered by gavage 1 week after modeling and continued for 4 weeks.

[0089] 2.2 Index detection

[0090] 2.2.1 Ovarian index test

[0091] 24 hours after the last administration, blood was collected from the eyeballs, the animals were killed by cervical dislocation, and the ovarian tissues were removed, weighed, and the ovarian index was calculated.

[0092] Ovarian index = ovarian mass / body mass

[0093] 2.2.2 Observation of ovarian morphology

[0094] After weighing the ovaries, fix them with 4% paraformaldehyde solution, dehydrate them with gradient alcohol, embed them in paraffin, slice them, dewax them, stain them with HE, and make pathological sections. Observe the morphological changes of normal follicles and atretic follicles in the ovaries.

[0095] 2.2.3 Immunohistochemistry

[0096] Immunohistochemistry SP two-step method was used to detect the expression of PI3K, AKT and bcl-2 proteins in the ovarian tissues of each group of mice. All sections were observed blindly under a microscope, and brown-yellow granules in ovarian granulosa cells were considered positive. The results were analyzed using the MIAS medical image analysis system, and the average optical density of positive expression was analyzed.

[0097] 2.2.4 Data processing

[0098] SPSS 22.0 software was used for statistical analysis, and the data were expressed as mean ± standard deviation ( ) indicated that one-way analysis of variance was used for analysis among multiple groups, and P < 0.05 was considered statistically significant.

[0099] 3 Experimental results

[0100] 3.1 Effects of the composition of the present invention on mouse organ indexes

[0101] The comparison of the ovarian index, thymus index and spleen index of each group of mice is shown in Table 3. Compared with the blank control group, the ovarian index of the model control group was significantly reduced (P < 0.01). Compared with the model control group, the ovarian index of the positive control group and the medium and high dose groups of the composition of the present invention was significantly increased (P < 0.05).

[0102] Table 3 Comparison of ovarian index of mice in each group (n=10, )

[0103]

[0104] Note: Compared with the blank control group, *P<0.05, **P<0.01; compared with the model control group, # P<0.05, ## P<0.01,### P<0.001.

[0105] 3.2 Effect of the composition of the present invention on the ovarian tissue morphology of mice in each group

[0106] The ovarian tissue structure of each group of mice was observed under a microscope. The ovarian structure of the blank control group was clear, and the morphology of the growing follicles at all levels was normal. The ovarian structure of the model control group was disordered, the primary and secondary follicles showed atresia-like changes, irregular arrangement, oocyte atrophy, and inflammatory infiltration was seen in the follicles. The structure of the follicular granulosa cells and oocytes in the positive control group was unclear, inflammatory infiltration was seen in the follicles, and the number of atretic follicles increased. The follicular granulosa cells in the low-dose group of the composition of the present invention had poor morphology, inflammatory infiltration was seen in some follicles, and several atretic follicles were seen. The ovarian structure of the medium-dose group was clear, and some follicles developed normally. The ovarian development of the high-dose group was basically normal, and a small number of atretic follicles were seen.

[0107] 3.3 Effect of the composition of the present invention on the expression of PI3K, AKT and Bcl-2 proteins in mice

[0108] The results of ovarian PI3K, AKT and Bcl-2 protein expression in each group of mice are shown in Table 4. Compared with the blank control group, the expression of PI3K, AKT and Bcl-2 proteins in the model control group was significantly reduced (P < 0.001); the expression of PI3K, AKT and Bcl-2 proteins in the mice in each drug administration group was upregulated to varying degrees. Compared with the model control group, the expression of the positive control group and the high-dose group of the composition of the present invention was most significantly upregulated (P < 0.001).

[0109] Table 4 Positive expression of PI3K, AKT and Bcl-2 in the ovaries of mice in each group (n=10, )

[0110]

[0111] Note: Compared with the blank control group, ***P < 0.001; compared with the model control group, # P<0.05, ## P<0.01, ### P<0.001.

[0112] The Chinese medicine composition of the present invention is guided by the theory of traditional Chinese medicine, starting from the overall perspective, mobilizing the overall function of the body in multiple dimensions and multiple links, improving the response of the ovaries to gonadotropins, and thus restoring and improving ovarian function. It can also avoid the adverse reactions and dependence caused by sex hormones, restore the function of the gonad axis, improve the disordered state of sex hormones, and stimulate the repair of the ovaries and other damaged tissues. It has obvious clinical efficacy and drug safety compared to the simple application of hormone regulation. DETAILED DESCRIPTION

[0113] The technical solution of the present application is further described below by way of example. It should be noted that the following examples are only used to illustrate the technical solution of the present invention and do not limit the protection scope of the present invention. Although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should all be included in the protection scope of the present invention.

[0114] Example 1 Preparation of granules

[0115]

[0116] (1) The above 18 raw medicinal materials are cleaned, washed and dried. Among them, cooked rehmannia, cyperus rotundus and chuanxiong are cut into thick slices; codonopsis pilosula and liquorice are soaked thoroughly, cut into thick slices and dried; fructus aurantii and angelica are soaked thoroughly, cut into thin slices and dried; motherwort is quickly washed, slightly moistened, cut and dried; antler powder and schisandra chinensis are crushed; tortoise shell is steamed in boiling water for 45 minutes, put in hot water to remove the skin and flesh, washed and dried; the rough skin of eucommia is scraped off, washed, cut into pieces and dried; the leaves of epimedium are picked, sprayed with clean water, slightly moistened, cut into strips and dried; and set aside for use;

[0117] (2) taking the 18 raw medicinal material slices processed in step (1) of the prescription amount, adding water and decocting twice, the first time adding 10 times of water and decocting for 2 hours, the second time adding 8 times of water and decocting for 1.5 hours; filtering, collecting and combining the decoctions, and concentrating under reduced pressure to an extract with a relative density of 1.26 at 50° C.-60° C.;

[0118] (3) The extract obtained in step (2) is vacuum dried to obtain a dry paste, and an appropriate amount of sucrose is added, and dry granulation and granulation are performed to obtain granules.

[0119] Example 2 Preparation of mixture

[0120]

[0121] (1) The above 18 raw medicinal materials are cleaned, washed and dried. Among them, cooked rehmannia, cyperus rotundus and chuanxiong are cut into thick slices; codonopsis pilosula and liquorice are soaked thoroughly, cut into thick slices and dried; fructus aurantii and angelica are soaked thoroughly, cut into thin slices and dried; motherwort is quickly washed, slightly moistened, cut and dried; antler powder and schisandra chinensis are crushed; tortoise shell is steamed in boiling water for 45 minutes, put in hot water to remove the skin and flesh, washed and dried; the rough skin of eucommia is scraped off, washed, cut into pieces and dried; the leaves of epimedium are picked, sprayed with clean water, slightly moistened, cut into strips and dried; and set aside for use;

[0122] (2) taking 10 raw medicinal material slices processed in step (1) of the prescription amount, adding water and decocting twice, the first time adding 8 times of water and decocting for 2 hours, the second time adding 6 times of water and decocting for 1 hour; filtering, collecting and combining the decoctions, and concentrating under reduced pressure to an extract with a relative density of 1.07 at 50-60° C.;

[0123] (3) adding ethanol to the extract obtained in step (2) until the alcohol content is 65%, cooling and precipitating for 48 hours, filtering and obtaining the alcohol precipitate for later use;

[0124] (4) recovering ethanol by vacuum concentration and concentrating to obtain an extract or a liquid for preparation; adding an appropriate amount of aspartame to correct the taste, adjusting the pH to 7.0, adding water to the total amount of preparation, stirring, filtering, filling, and sterilizing to obtain a mixture.

[0125] Example 3 Preparation of tablets

[0126]

[0127] (1) The above 18 raw medicinal materials are cleaned, washed and dried. Among them, cooked rehmannia, cyperus rotundus and chuanxiong are cut into thick slices; codonopsis pilosula and liquorice are soaked thoroughly, cut into thick slices and dried; fructus aurantii and angelica are soaked thoroughly, cut into thin slices and dried; motherwort is quickly washed, slightly moistened, cut and dried; antler powder and schisandra chinensis are crushed; tortoise shell is steamed in boiling water for 45 minutes, put in hot water to remove the skin and flesh, washed and dried; the rough skin of eucommia is scraped off, washed, cut into pieces and dried; the leaves of epimedium are picked, sprayed with clean water, slightly moistened, cut into strips and dried; and set aside for use;

[0128] (2) taking the 18 raw medicinal material slices processed in step (1) of the prescription amount, adding water and decocting twice, the first time adding 12 times of water and decocting for 2 hours, the second time adding 10 times of water and decocting for 1.5 hours; filtering, collecting and combining the decoctions, and concentrating under reduced pressure to an extract with a relative density of 1.21 at 50° C.-60° C.;

[0129] (3) adding ethanol to the extract obtained in step (2) until the alcohol content is 75%, cooling and settling for 48 hours, filtering and obtaining the alcohol precipitate for later use;

[0130] (4) recovering ethanol by vacuum concentration and concentrating, vacuum drying to obtain a dry paste, crushing the dry paste, adding appropriate amounts of starch, magnesium stearate and other auxiliary materials, mixing well, and pressing to obtain tablets.

[0131] Example 4 Preparation of capsules

[0132]

[0133] (1) The above 18 raw medicinal materials are cleaned, washed and dried. Among them, cooked rehmannia, cyperus rotundus and chuanxiong are cut into thick slices; codonopsis pilosula and liquorice are soaked thoroughly, cut into thick slices and dried; fructus aurantii and angelica are soaked thoroughly, cut into thin slices and dried; motherwort is quickly washed, slightly moistened, cut and dried; antler powder and schisandra chinensis are crushed; tortoise shell is steamed in boiling water for 45 minutes, put in hot water to remove the skin and flesh, washed and dried; the rough skin of eucommia is scraped off, washed, cut into pieces and dried; the leaves of epimedium are picked, sprayed with clean water, slightly moistened, cut into strips and dried; and set aside for use;

[0134] (2) taking the 18 raw medicinal material slices processed in step (1) of the prescription amount, adding water and decocting twice, the first time adding 10 times of water and decocting for 2 hours, the second time adding 8 times of water and decocting for 1 hour; filtering, collecting and combining the decoctions, and concentrating under reduced pressure to an extract with a relative density of 1.23 at 50° C.-60° C.;

[0135] (3) adding ethanol to the extract obtained in step (2) until the alcohol content is 60%, cooling and precipitating for 48 hours, filtering and obtaining the alcohol precipitate for later use;

[0136] (4) recovering ethanol by vacuum concentration and concentrating, vacuum drying to obtain a dry paste, crushing the dry paste into fine particles, and filling the particles into capsule shells to obtain capsules.

[0137] Comparative Example 1

[0138]

[0139] The above 20 raw medicinal materials were cleaned and removed of impurities, pre-treated according to the pharmacopoeia method, decocted with water twice, 8 times the amount of water was added for the first time and decocted for 2 hours, and 6 times the amount of water was added for the second time and decocted for 1 hour. The decoctions were combined and concentrated under reduced pressure to about 500 ml of concentrated decoction.

[0140] Comparative Example 2

[0141]

[0142]

[0143] The above 12 raw medicinal materials were cleaned and removed of impurities, pre-treated according to the pharmacopoeia method, decocted with water twice, 8 times the amount of water was added for the first time and decocted for 2 hours, and 6 times the amount of water was added for the second time and decocted for 1 hour. The decoctions were combined and concentrated under reduced pressure to 500 ml of concentrated decoction.

Claims

1. A Chinese medicine composition for treating secondary amenorrhea caused by ovarian failure, the Chinese medicine composition comprising the following Chinese medicine components: 9-15 parts by weight of Rehmannia glutinosa 6-12 parts by weight of Lycium barbarum 6-12 parts by weight of Cuscuta chinensis 6-12 parts by weight 6-12 parts by weight of Chinese Angelicae Sinensis 9-30 parts by weight of Codonopsis Pilosula 6-12 parts by weight of Ligustrum lucidum 9-15 parts by weight of antler cream 9-24 parts by weight of tortoise shell 6-10 parts by weight of Eucommia ulmoides 6-10 parts by weight of Cyperus rotundus 3-10 parts by weight of Fructus Aurantii Immaturus 2-10 parts by weight of Licorice Epimedium 6-10 weight parts Raspberry 6-12 weight parts Schisandra 2-6 weight parts 9-30 parts by weight of Leonurus japonicus, 3-10 parts by weight of Ligusticum chuanxiong, and 5-10 parts by weight of Fructus Smilacis Glabrae.

2. The Chinese medicine composition according to claim 1, characterized in that The Chinese medicine composition is composed of the following Chinese medicine components: 12-15 parts by weight of Rehmannia glutinosa 10-12 parts by weight of Lycium barbarum 10-12 parts by weight of Cuscuta australis 10-12 parts by weight 8-10 parts by weight of Chinese Angelica Root 15-20 parts by weight of Codonopsis Pilosula 10-12 parts by weight of Ligustrum Lucidum Fruit Deer antler cream 12-15 weight parts Tortoise shell 15-20 weight parts Eucommia ulmoides 8-10 weight parts 8-10 parts by weight of Cyperus rotundus 8-10 parts by weight of Fructus Aurantii Immaturus 6-10 parts by weight of Radix Glycyrrhizae Epimedium 8-10 weight parts Raspberry 9-12 weight parts Schisandra 3-5 weight parts 15-20 parts by weight of Leonurus japonicus, 6-10 parts by weight of Ligusticum chuanxiong, and 8-10 parts by weight of Fructus Smilacis Glabrae.

3. A medicine, characterized in that: The composition is prepared from the Chinese medicine composition described in claim 1 or 2 as raw material.

4. The medicine according to claim 3, characterized in that The medicine is in the form of granules, mixtures, pills, capsules or tablets.

5. The Chinese medicine composition according to claim 1, characterized in that: The amenorrhea is of liver and kidney deficiency type or yin deficiency and blood dryness type.